Approved for use through 10/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond 0 is collection of information unless of displays a valid Orthor lumber.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) SWRI-2890-04
	SW(1-2090-04
In re Application of: Ronghua WEI	
Application No.: 10/693,076	
Filed: 10/24/2003	
For: Tubular Structures with Coated Interior Surfaces	
The owner", <u>Southwest Research Institute</u> of 100 percent Interest in the instant application interby disclaims, except as provided below, the terminal part of the stantucy term of any patent grarent on the instant application which would sets by all due except as provided below, the certificial interest of the stantucy terminal disclaims and the certificial interest of the stantucy terminal disclaims. The owner here they applied and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees they applied to a prior patent as organized on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent grared on the instant application and is blinding upon the grarinet, its successors or assigns.	
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in \$5 U.S. C. 154 and 175 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: express for failure to pay a maintenance fee; is held unenforceable; is held unenforceable; is found in valuable by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate, in all claims canceled by a reexamination certificate, is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.	
Check either box 1 or 2 below, if appropriate.	
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. 	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made do information and belief are believed to be true; and urther that these statements were made with the knowledge that willight false statements were made are punishable by fine or imprisonment, or both, under Section 1001 of 18te 18 of the United States Code and that such willful false statements may loopardize the validity of the application or any patient issued thereon.	
2. V The undersigned is an attorney or agent of record. Reg. No. 31,516	
Fund Mozar Signature	10-26-0-7 Date
Paula D. Morris	
	(713) 334-5151, ext. 200 Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CER J. 321. The information is required to obtain or return a benefit by the public which is to fixe (end by the USETO to possess) am spingation. Confidentiality is governed by 30 List. 12 and 37 CER J. 11 and 11.4. This collection is estimated to take 12 minutes to complete, including quathering, preparing, and submitting the completed application from to the USETO. Then will vary depending upon the individual case. Any comments on the amount of time pour requires to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer. U.S. Patient and Trasfarmak Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND 17 Commissioner for Patients, P.O. Box 1450, Alexandria, VA. 2213-1450.